Don’t miss – Page 175 – Endpoints News

SIGN UP

Controversial Duchenne MD player Solid Bio takes another hit, laying off staffers in a bid to weather FDA hold

4 years ago

Regeneron’s pivotal trial for an ultra-rare disease fails the primary — but don't count them out at the FDA

4 years ago

Sanofi antes up $55M to add protein degradation tech to the R&D playbook as execs look to revive the pipeline

4 years ago

Merck's Keytruda wins another first — this time for an FDA nod to treat a subset of bladder cancer patients

4 years ago

ADC Therapeutics clears a big hurdle toward its first BLA as pivotal PhII delivers upbeat ORR results

4 years ago

Scoop: Sanofi quietly ties up with a low-profile, preclinical cancer biotech — FTC signs off

4 years ago

Thomas Lynch finds a new home as leader of the Fred Hutch — and he’s staying focused on cancer breakthroughs

4 years ago

Apellis soars as Alexion rival outshines blockbuster standard bearer Soliris — then fresh doubts scuttle spike

4 years ago

A Bay Area biotech spells out the stock package it used to woo a new CEO from Big Pharma

4 years ago

Fresh from a Pfizer buyout, Luca Santarelli’s crew has created a new company — banking new funds and steering their lead drug to a pivotal

4 years ago

Merck's PD-1 star Keytruda flunks a key survival endpoint in SCLC — cue the unfavorable Tecentriq comparisons

4 years ago

As questions swirl around lead drug, FibroGen (and AstraZeneca) find a new champion from Big Pharma

4 years ago

Merck dives deeper into KRAS, teaming up with Taiho, Astex to develop small molecule drugs

4 years ago

FDA offers AstraZeneca a shortcut on a landmark SGLT2 approval while China greenlights Lokelma

4 years ago

Illumina's $1.2B buyout dies amid FTC 'monopolist' accusation

4 years ago

Incyte takes a beating as a key PhIII study flops in their latest painful setback — blockbuster hopes crushed

4 years ago

Biotech billionaire spends $88M to reorganize his long-suffering bioengineering businesses, hands off CEO role

4 years ago

‘No one expects to get a knighthood’: AstraZeneca’s Mene Pangalos knighted for his leading role in UK life sciences

4 years ago

Wave spotlights ‘positive’ data on Huntington’s drug, but stock takes a beating as Roche, Ionis rival stays in front

4 years ago

Antibiotics apocalypse: Melinta files for bankruptcy protection as a plague of woes afflicts the field

4 years ago

On a spree, Astellas bags a next-gen, Parker-backed CAR-T platform with $665M buyout deal

4 years ago

Biotech takes a Christmas beating after safety fears force researchers to halt all hep B studies

4 years ago

Spectrum shares crater as first round of pivotal data for their TKI falls short of primary endpoint

4 years ago

The top 10 most popular Endpoints News pieces of 2019 — going viral is a whole new game in biopharma now

4 years ago

First page Previous page 172 173 174175176 177 178 Next page Last page